Selecting Androgen Receptor Pathway Inhibitors in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan asks Dr. Jayram to discuss the key clinical considerations that guide the selection of androgen receptor pathway inhibitors when intensifying therapy for metastatic castration sensitive prostate cancer (mCSPC). Dr. Jayram explains that treatment choice often depends on multiple patient and disease related factors, including comorbid conditions, concurrent medications, and the patient’s overall functional status. He highlights that clinicians must carefully evaluate the potential for drug–drug interactions, particularly in patients who are already receiving several medications for chronic conditions. The discussion also touches on safety considerations such as cardiovascular risk, metabolic health, and long term tolerability, which may influence therapy selection in everyday clinical practice. Dr. Jayram emphasizes that while clinical trial evidence provides a strong foundation, individualized treatment decisions remain essential. This segment highlights how physicians integrate patient specific characteristics with available evidence to guide androgen receptor pathway inhibitor selection in metastatic castration sensitive prostate cancer.